

Treatments compared for pediatric-onset multiple sclerosis

October 6 2022



More patients with pediatric-onset multiple sclerosis (POMS) are free of

new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β -1a (IFN β -1a) treatment, and the annualized relapse rate is lower with DMF, according to a study published online Sept. 28 in *JAMA Network Open*.

Patrick Vermersch, M.D., Ph.D., from the Centre Hospitalier Universitaire de Lille in France, and colleagues conducted an active-controlled, open-label randomized clinical trial involving patients with POMS aged 10 to

Citation: Treatments compared for pediatric-onset multiple sclerosis (2022, October 6) retrieved 11 August 2024 from

<https://medicalxpress.com/news/2022-10-treatments-pediatric-onset-multiple-sclerosis.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.